Kate Therapeutics, a San Diego, CA-based gene therapy company, raised $51M in Series A funding.
The round was led by Westlake Village BioPartners and Versant Ventures with participation from Osage University Partners and UF Innovate | Ventures.
The company intends to use the funds to support the advancement of its initial internal portfolio of muscle and heart disease programs, including myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), which are two of the leading causes of adult-onset muscular dystrophy.
Led by Kevin Forrest, Ph.D., president, CEO and director, KateTx is a patient-centric biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of genetically defined muscle and heart diseases that apply new technology platforms that directly address major limitations of current gene therapies, including tissue-specific delivery and gene regulation. These have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of goals otherwise difficult to address with current technologies.
FinSMEs
08/06/2023